Akshay Gopinathan Nair1, Haresh T Asnani2, Vinod C Mehta3, Siddharth V Mehta3, Rima S Pathak4, Amit H Palkar5, Indumati Gopinathan6. 1. Advanced Eye Hospital and Institute, Mumbai, India; Aditya Jyot Eye Hospital, Mumbai, India; Mehta Eye Clinic Pvt. Ltd, Mumbai, India; Lokmanya Tilak Municipal Medical College and Hospital, Mumbai, India. 2. Advanced Eye Hospital and Institute, Mumbai, India; Mehta Eye Clinic Pvt. Ltd, Mumbai, India. 3. Mehta Eye Clinic Pvt. Ltd, Mumbai, India. 4. Tata Memorial Cancer Hospital, Mumbai, India; British Columbia Cancer Agency, Abbotsford, B.C., Canada. 5. Lokmanya Tilak Municipal Medical College and Hospital, Mumbai, India. 6. Clinico-Path Labs, Mumbai, India.
Abstract
BACKGROUND: Choroidal metastases being the sole presenting feature of lung cancer is rare. Erlotinib, a tyrosine kinase inhibitor (TKI), is used in the treatment of lung adenocarcinoma where tumor cells exhibit epidermal growth factor receptor (EGFR) mutations. We report a case of metastatic non-small-cell lung cancer (NSCLC) with choroidal metastasis, which was the sole presenting feature and which responded to erlotinib. METHODS: We performed a retrospective case review. CASE: A 78-year-old man presented with a choroidal mass which was found to be the presenting feature of metastatic NSCLC. Our patient, a nonsmoker, had disseminated bony metastases, and therefore was advised to undergo palliative chemotherapy, which he refused. He was therefore instituted on oral erlotinib. RESULTS: Tumor cells expressing EGFR mutations are known to be susceptible to TKIs. Even though the tumor in our case showed no mutation, i.e. was classified as 'wild-type', our patient showed a dramatic response to erlotinib. At 1 year, the choroidal lesion had regressed and visual acuity had recovered. CONCLUSIONS: TKIs may be beneficial in patients with choroidal metastases from NSCLC, especially those in which an EGFR mutation is noted. Even in the absence of such mutations, choroidal metastases may show a favorable effect in response to TKIs, such as erlotinib.
BACKGROUND:Choroidal metastases being the sole presenting feature of lung cancer is rare. Erlotinib, a tyrosine kinase inhibitor (TKI), is used in the treatment of lung adenocarcinoma where tumor cells exhibit epidermal growth factor receptor (EGFR) mutations. We report a case of metastatic non-small-cell lung cancer (NSCLC) with choroidal metastasis, which was the sole presenting feature and which responded to erlotinib. METHODS: We performed a retrospective case review. CASE: A 78-year-old man presented with a choroidal mass which was found to be the presenting feature of metastatic NSCLC. Our patient, a nonsmoker, had disseminated bony metastases, and therefore was advised to undergo palliative chemotherapy, which he refused. He was therefore instituted on oral erlotinib. RESULTS:Tumor cells expressing EGFR mutations are known to be susceptible to TKIs. Even though the tumor in our case showed no mutation, i.e. was classified as 'wild-type', our patient showed a dramatic response to erlotinib. At 1 year, the choroidal lesion had regressed and visual acuity had recovered. CONCLUSIONS: TKIs may be beneficial in patients with choroidal metastases from NSCLC, especially those in which an EGFR mutation is noted. Even in the absence of such mutations, choroidal metastases may show a favorable effect in response to TKIs, such as erlotinib.
Authors: V Noronha; R Dikshit; N Raut; A Joshi; C S Pramesh; K George; J P Agarwal; A Munshi; K Prabhash Journal: Indian J Cancer Date: 2012 Jan-Mar Impact factor: 1.224
Authors: Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard Journal: Lancet Date: 2008-11-22 Impact factor: 79.321
Authors: A D Bhatt; R Pai; G Rebekah; G Arun Nehru; S Dhananjayan; A Samuel; A Singh; A Joel; A Korula; R T Chacko Journal: Indian J Cancer Date: 2013 Apr-Jun Impact factor: 1.224